会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ERBB SURFACE RECEPTOR COMPLEXES AS BIOMARKERS
    • ERBB表面受体复合物作为生物标志物
    • WO2004091384A3
    • 2005-12-29
    • PCT/US2004009715
    • 2004-03-30
    • ACLARA BIOSCIENCES INCCHAN-HUI PO-YINGSALIMI-MOOSAVI HOSSEINSHI YININGSINGH SHARATDUA RAJIVMUKHERJEE ALIPIDAPARTHI SAILAJA
    • CHAN-HUI PO-YINGSALIMI-MOOSAVI HOSSEINSHI YININGSINGH SHARATDUA RAJIVMUKHERJEE ALIPIDAPARTHI SAILAJA
    • A61B20060101C07K16/28C12N20060101C12Q3/00G01N33/542G01N33/543G01N33/574
    • G01N33/57492C07K16/2863G01N33/542G01N2333/485G01N2800/52
    • The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
    • 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。
    • 4. 发明申请
    • INTRACELLULAR COMPLEXES AS BIOMARKERS
    • 细胞内复合物作为生物标志物
    • WO2004087887A2
    • 2004-10-14
    • PCT/US2004009805
    • 2004-03-30
    • ACLARA BIOSCIENCES INCSINGH SHARATBADAL M YOUSSOUFJIN XUENGUANGSALIMI-MOOSAVI HOSSEIN
    • SINGH SHARATBADAL M YOUSSOUFJIN XUENGUANGSALIMI-MOOSAVI HOSSEIN
    • A61B20060101C07K16/28C12N20060101C12Q3/00G01N33/542G01N33/543G01N33/574C12N
    • G01N33/57492C07K16/2863G01N33/542G01N2333/485G01N2800/52
    • The invention provides a method for determining a disease status of a patient by measuring expression levels of selected intracellular complexes. In one aspect of the invention, the activation status of apoptotic pathways in a patient sample is determined by measuring relative amounts of protein-protein complexes that are characteristic of the apoptotic pathways. In particular, the invention provides a method of determining the activation status of the mitochondrial apoptotic pathway by simultaneously measuring relative amounts of complexes between 14-3-3 proteins and BAD proteins on the one hand and complexes of Bcl-2 proteins and BAD proteins on the other hand. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed within apoptotic pathways. After binding molecular tags are released and separated from the assay mixture for analysis.
    • 本发明提供了一种通过测量所选细胞内复合物的表达水平来确定患者的疾病状态的方法。 在本发明的一个方面,通过测量凋亡通路特征的蛋白质 - 蛋白质复合物的相对量来确定患者样品中凋亡途径的活化状态。 特别地,本发明提供了一种通过同时测量14-3-3蛋白和BAD蛋白之间的复合物的相对量以及Bcl-2蛋白和BAD蛋白的复合物的相对量来确定线粒体凋亡途径的激活状态的方法 另一方面。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物组来实现,所述可释放分子标签对在凋亡途径内形成的一种或多种复合物的多种组分是特异性的。 结合分子标签后,从测定混合物中分离出分子标签进行分析。
    • 5. 发明申请
    • DETECTING HUMAN ANTI-THERAPEUTIC ANTIBODIES
    • 检测人体抗病毒抗体
    • WO2005045058A3
    • 2005-12-08
    • PCT/US2004035079
    • 2004-10-25
    • ACLARA BIOSCIENCES INCSALIMI-MOOSAVI HOSSEINKIRAKOSSIAN HRAIRSINGH SHARAT
    • SALIMI-MOOSAVI HOSSEINKIRAKOSSIAN HRAIRSINGH SHARAT
    • C12Q20060101G01N27/26G01N33/53G01N33/537G01N33/543G01N33/68G01N33/94
    • G01N33/6854G01N33/94
    • The invention provides a method for detecting the presence of anti-therapeutic antibody antibodies in a patient being treated with a therapeutic antibody. In one aspect of the invention, the invention is implemented by the following steps: (i) providing a first therapeutic antibody having a molecular tag attached thereto by a cleavable linkage, the molecular tag having one or more predetermined separation characteristics; (ii) providing a second therapeutic antibody having a cleavage-inducing moiety attached thereto, the cleavage-inducing moiety having an effective proximity; (iii) combining in an assay mixture the sample, the first therapeutic antibody, and the second therapeutic antibody under condition such that the first and second therapeutic antibodies form a complex with an anti-therapeutic antibody wherein the cleavable linkage of the first therapeutic antibody is within the effective proximity of the cleavage-inducing moiety of the second therapeutic antibody and molecular tags are released; and (iv) separating from the assay mixture and detecting the released molecular tags to determine the presence or absence of anti-therapeutic antibodies in the sample.
    • 本发明提供了用于检测正在用治疗性抗体治疗的患者中抗 - 治疗性抗体抗体的存在的方法。 在本发明的一个方面中,通过以下步骤实施本发明:(i)提供具有通过可切割连接与其连接的分子标签的第一治疗性抗体,所述分子标签具有一种或多种预定分离特征; (ii)提供具有与其连接的切割诱导部分的第二种治疗性抗体,所述切割诱导部分具有有效的接近性; (iii)在使得第一和第二治疗性抗体与抗治疗性抗体形成复合物的条件下,在测定混合物中组合样品,第一治疗性抗体和第二治疗性抗体,其中第一治疗性抗体的可切割的连接是 在第二治疗性抗体的切割诱导部分的有效接近范围内并释放分子标签; 和(iv)从测定混合物中分离并检测释放的分子标签以确定样品中是否存在抗治疗性抗体。
    • 6. 发明申请
    • METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS
    • 分析蛋白质的方法和组合物
    • WO02095356A3
    • 2004-12-23
    • PCT/US0216098
    • 2002-05-21
    • ACLARA BIOSCIENCES INCSINGH SHARATSALIMI-MOOSAVI HOSSEINTAHIR SYED HASANWALLWEBER GERALD JKIRAKOSSIAN HRAIRMATRAY TRACY JHERNANDEZ VINCENT S
    • SINGH SHARATSALIMI-MOOSAVI HOSSEINTAHIR SYED HASANWALLWEBER GERALD JKIRAKOSSIAN HRAIRMATRAY TRACY JHERNANDEZ VINCENT S
    • G01N33/483G01N21/78G01N27/447G01N33/53G01N33/536G01N33/68
    • G01N33/6842C07K16/00C07K2317/40G01N33/582G01N33/6803
    • Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.
    • 公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法,组合物和试剂盒。 包含样品和包含切割诱导部分和用于靶多肽上的结合位点的第一结合剂的第一试剂的混合物经受各自结合部分的结合发生的条件。 结合位点是涉及靶多肽的翻译后修饰活性的结果。 该方法可用于确定靶多肽本身。 在另一个实施方案中,靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。 第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近与多肽相关的可切割部分,并且仅在接近切割诱导部分时易于切割。 以这种方式,可以释放每个多肽的电泳标签。 分离出释放的电泳标签,并且基于相应的电泳标签确定靶多肽的存在和/或量。